Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.

Acquired haemophilia A is a very rare (1-2 cases per million people) but often life-threatening haemorrhagic disorder characterized by antibodies directed against coagulation factor VIII. We report the case of a 55-year old woman under treatment with Pegylated alpha 2a interferon (IFN) and Ribavirin for chronic viral C hepatitis, who developed a progressive severe haemorrhagic syndrome diagnosed as acquired haemophilia based on supplementary laboratory data (prolonged activated partial thromboplastin time, extremely low factor VIII level - 1%, high titre of factor VIII inhibitor - 30 Bethesda U/ml).The onset was insidious, about three months before presenting to our unit. Antiviral therapy had been stopped three weeks before current admission. Emergency intensive treatment included: haemostatic agents - rFVII (Novoseven), FEIBA (Factor VIII Inhibitor Bypassing Activity), vitamin K, adrenostazin, cryoprecipitate, fresh frozen plasma, as well as immunosuppressive therapy (high dose corticotherapy and cyclophoshamide), immunoglobulins (Humaglobin), prophylactic PPI and antibiotics. The evolution was slowly favourable with the remission of the haemorrhagic syndrome and regression of the iliopsoas muscle haematoma. Clinicians should be aware that acquired forms of haemophilia do exist, representing a rare diagnosis and a therapeutic challenge. To our knowledge, this is the first reported case of acquired haemophilia in Romania, in a patient with chronic viral C hepatitis under antiviral treatment.

[1]  P. Collins,et al.  Management of acquired haemophilia A , 2011, Journal of thrombosis and haemostasis : JTH.

[2]  M. Campos-de-Magalhães,et al.  Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin , 2011, Hematology.

[3]  G. Conté L,et al.  [Acquired hemophilia A treated with rituximab. Report of one case]. , 2011, Revista medica de Chile.

[4]  C. Kessler,et al.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A , 2009, Haematologica.

[5]  G. Lippi,et al.  Drug-induced anti-factor VIII antibodies: a systematic review. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[6]  M. Franchini,et al.  Acquired hemophilia A. , 2011, Advances in clinical chemistry.

[7]  N. Bräu,et al.  Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon‐α: A case report , 2005, American journal of hematology.

[8]  L. Boggio,et al.  Factor VIII inhibitor associated with peginterferon , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  A. Anagnostopoulos,et al.  Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a , 2004, Bone Marrow Transplantation.

[10]  Y. Gruel,et al.  Acquired inhibitor to factor VIII in a patient with Hodgkin’s disease following treatment with interferon‐alpha , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  M. Kovacs,et al.  Acquired Factor VIII Inhibitor in a Patient with Chronic Myelogenous Leukemia Receiving Interferon-Alfa Therapy , 2000, The Annals of pharmacotherapy.

[12]  R. Chamuleau,et al.  Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C , 1996, Annals of Internal Medicine.

[13]  B. Colvin,et al.  Acquired factor VIII inhibitor associated with chronic interferon‐alpha therapy in a patient with haemophilia A , 1994, British journal of haematology.